PDT

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

Retrieved on: 
Wednesday, April 10, 2024

TG4050 is based on Transgene's myvac platform and powered by NEC's cutting-edge AI capabilities designed to optimize antigen selection.

Key Points: 
  • TG4050 is based on Transgene's myvac platform and powered by NEC's cutting-edge AI capabilities designed to optimize antigen selection.
  • TG4050 is starting to show a potential benefit for head and neck cancer patients at high risk of relapse.
  • We look forward to starting the Phase II part of the trial in the adjuvant setting for head and neck cancer."
  • The poster can be viewed in-person during the poster presentation at the AACR 2024 meeting and accessed on Transgene's website.

Cadence’s Nimish Modi to Present at Needham Conference

Retrieved on: 
Thursday, May 9, 2024

Nimish Modi, senior vice president and general manager, Strategy & New Ventures, Cadence Design Systems, Inc. (Nasdaq: CDNS).

Key Points: 
  • Nimish Modi, senior vice president and general manager, Strategy & New Ventures, Cadence Design Systems, Inc. (Nasdaq: CDNS).
  • Modi will participate in a virtual fireside chat at the 19th Annual Needham Technology, Media, & Consumer Conference on Thursday, May 16, 2024.
  • The talk will be available live by webcast at 9:45 a.m. PDT on Thursday, May 16, 2024.
  • The presentation will be archived on the Cadence website and will be available for replay for 90 days.

Nevro to Present at BofA Securities 2024 Healthcare Conference

Retrieved on: 
Thursday, May 9, 2024

REDWOOD CITY, Calif., May 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, 2024.

Key Points: 
  • REDWOOD CITY, Calif., May 9, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that members of its management team will participate in the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, 2024.
  • The company's formal presentation will begin at 9:20 am PDT (12:20 am EDT).
  • Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com .
  • The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

Solventum Reports First Quarter 2024 Financial Results and Capital Allocation Update

Retrieved on: 
Thursday, May 9, 2024

Solventum now expects an unfavorable impact from foreign exchange of ~50bps on reported sales for the full year 2024.

Key Points: 
  • Solventum now expects an unfavorable impact from foreign exchange of ~50bps on reported sales for the full year 2024.
  • 3M supply agreement mark-up started on April 1, 2024, and Solventum anticipates impact to the income statement to begin largely in the second half of 2024.
  • Solventum's full-year 2024 guidance is based on Q1 2024 3M carve-out financial information and expected results for the remainder of the year as a stand-alone company, starting April 1, 2024.
  • The Q1 2024 financial statements and financial information, including reconciliations of non-GAAP financial measures and certain prior period reconciliations, are available on Solventum's website: https://investors.solventum.com .

Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024

Retrieved on: 
Thursday, May 9, 2024

THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024.

Key Points: 
  • THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024.
  • Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentation on Tuesday, May 14, 2024, at 8:00 am PDT (11:00 am ET).
  • A simultaneous webcast will be available in the “Events” section of the Lexicon website at www.lexpharma.com/events , and a recording of the webcast will be available for two weeks following the original on-demand date.

LogicMark, Inc. to Present at Aegis Capital Corp. Virtual Conference on May 9, 2024

Retrieved on: 
Wednesday, May 8, 2024

LOUISVILLE, Ky., May 08, 2024 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK), a provider of personal emergency response systems (PERS), health communications devices, and technology for the growing care economy, today announced that Ms. Chia-Lin Simmons, CEO, and Mr. Mark Archer, CFO will speak at the virtual Aegis Capital Corp. Conference on Thursday, May 9th at 11:00 PDT / 2:00 pm EDT.

Key Points: 
  • LOUISVILLE, Ky., May 08, 2024 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK), a provider of personal emergency response systems (PERS), health communications devices, and technology for the growing care economy, today announced that Ms. Chia-Lin Simmons, CEO, and Mr. Mark Archer, CFO will speak at the virtual Aegis Capital Corp. Conference on Thursday, May 9th at 11:00 PDT / 2:00 pm EDT.
  • Please register here to attend the conference:

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

Retrieved on: 
Wednesday, May 8, 2024

“These data build on more than a decade of innovation at CytomX, and, we believe, open broad new possibilities for T-cell engagers across many targets and cancer types.

Key Points: 
  • “These data build on more than a decade of innovation at CytomX, and, we believe, open broad new possibilities for T-cell engagers across many targets and cancer types.
  • CX-904 Phase 1a dose escalation and optimization continue, with future enrollment focused on determining a recommended Phase 2 dose, or doses.
  • The Company expects to provide an additional Phase 1a dose escalation update by the end of 2024.
  • These additional data will inform discussions with CytomX partner, Amgen, towards initiation of Phase 1b expansion cohorts in specific EGFR positive tumor types.

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 8, 2024

Initial data anticipated in 2025 -

Key Points: 
  • Initial data anticipated in 2025 -
    - Management to hold conference call today at 5 p.m. EDT / 2 p.m. PDT -
    SOUTH SAN FRANCISCO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today reported first quarter 2024 financial results and provided a business update.
  • The Company expects to provide an additional Phase 1a dose escalation update by the end of 2024.
  • The cash balance as of March 31, 2024, does not include the $10.0 million of Astellas milestone achievements earned in the first quarter of 2024.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

Fractyl Health to Present at BofA Securities 2024 Health Care Conference

Retrieved on: 
Wednesday, May 8, 2024

BURLINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that Dr. Harith Rajagopalan, CEO of Fractyl Health, will participate in a fireside chat at the upcoming BofA Securities 2024 Health Care Conference on Wednesday, May 15, 2024, at 4:20 p.m. PDT (7:20 p.m. EDT).

Key Points: 
  • BURLINGTON, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced that Dr. Harith Rajagopalan, CEO of Fractyl Health, will participate in a fireside chat at the upcoming BofA Securities 2024 Health Care Conference on Wednesday, May 15, 2024, at 4:20 p.m. PDT (7:20 p.m. EDT).
  • To register in advance for the fireside chat webcast, sign up here .

LogicMark, Inc. to Present at Virtual Emerging Growth Conference on May 8, 2024

Retrieved on: 
Tuesday, May 7, 2024

LOUISVILLE, K.Y., May 07, 2024 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK), a provider of personal emergency response systems (PERS), health communications devices, and technology for the growing care economy, today announced that Ms. Chia-Lin Simmons, CEO, will speak at the Emerging Growth Conference on May 8th at 11:20 PDT / 2:20 pm EDT.

Key Points: 
  • LOUISVILLE, K.Y., May 07, 2024 (GLOBE NEWSWIRE) -- LogicMark, Inc. (Nasdaq: LGMK), a provider of personal emergency response systems (PERS), health communications devices, and technology for the growing care economy, today announced that Ms. Chia-Lin Simmons, CEO, will speak at the Emerging Growth Conference on May 8th at 11:20 PDT / 2:20 pm EDT.
  • LogicMark invites individual and institutional investors, advisors, and analysts to attend its real-time, virtual presentation.
  • Please register here to attend the conference and receive any updates that are released.
  • https://goto.webcasts.com/starthere.jsp?ei=1658202&tp_key=3a47c30b43&sti...
    If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference , with a replay link provided after the event.